Published in JAMA on June 15, 1994
Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother (1996) 10.56
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother (1996) 8.65
mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 4.38
Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol (1997) 4.28
A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ (1998) 3.46
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health (2000) 2.57
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1995) 2.50
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother (1999) 2.49
Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun (2002) 2.25
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1996) 1.90
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother (1998) 1.79
Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. CMAJ (1998) 1.78
Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B. Infect Immun (2001) 1.77
In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 1.75
Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother (1999) 1.75
Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol (1999) 1.74
Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother (1996) 1.74
Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species. Antimicrob Agents Chemother (2003) 1.70
Evaluation of commercial methods for determining antimicrobial susceptibility of Streptococcus pneumoniae. J Clin Microbiol (1996) 1.68
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Antimicrob Agents Chemother (1997) 1.61
Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa. Antimicrob Agents Chemother (2001) 1.60
Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice. Can Fam Physician (1998) 1.59
Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother (1996) 1.51
Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother (2000) 1.49
Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother (2000) 1.48
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother (2005) 1.40
Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother (2004) 1.36
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.34
Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B. Infect Immun (1999) 1.32
Pneumococcal resistance to antimicrobial agents in the province of Québec, Canada. J Clin Microbiol (1994) 1.26
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1996) 1.24
Detection of penicillin-resistant Streptococcus pneumoniae with commercially available broth microdilution panels. J Clin Microbiol (1995) 1.23
Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 1.23
Emerging resistance to antimicrobial agents in gram-positive bacteria. Pneumococci. Drugs (1996) 1.23
Tracking drug-resistant Streptococcus pneumoniae in Oregon: an alternative surveillance method. Emerg Infect Dis (1999) 1.21
Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies. J Clin Microbiol (2000) 1.20
Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother (1996) 1.18
Immunoreactivity of five monoclonal antibodies against the 37-kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae. Clin Diagn Lab Immunol (1998) 1.16
MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob Agents Chemother (1997) 1.12
Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob Agents Chemother (2001) 1.12
Prevalence of antimicrobial drug-resistant Streptococcus pneumoniae in Washington State. West J Med (1998) 1.12
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother (1997) 1.09
Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1997) 1.09
Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother (1998) 1.09
Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams. Antimicrob Agents Chemother (1997) 1.08
Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect Immun (2000) 1.08
A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens. Can J Infect Dis (1999) 1.07
Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2. J Clin Microbiol (2000) 1.06
Antibiotic susceptibility patterns of Streptococcus pneumoniae in china and comparison of MICs by agar dilution and E-test methods. Antimicrob Agents Chemother (1998) 1.04
Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob Agents Chemother (1996) 1.04
Evaluation of the Dade MicroScan MICroSTREP antimicrobial susceptibility testing panel with selected Streptococcus pneumoniae challenge strains and recent clinical isolates. J Clin Microbiol (1998) 1.03
Laboratory survey of drug-resistant Streptococcus pneumoniae in New York City, 1993-1995. Emerg Infect Dis (1998) 1.02
Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect Immun (2001) 1.01
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother (1996) 1.01
Drug-resistant pneumococcal infections in the United States. A problem for clinicians, laboratories, and public health. JAMA (1994) 1.01
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1996) 0.98
Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob Agents Chemother (2001) 0.97
Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. Infect Immun (2001) 0.97
Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats. Antimicrob Agents Chemother (1997) 0.96
Reporting Emerging Resistance of Streptococcus pneumoniae from India. J Glob Infect Dis (2010) 0.96
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (2007) 0.94
Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging Dis (2011) 0.93
Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol (1996) 0.93
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Antimicrob Agents Chemother (2004) 0.93
Pneumococcal resistance in southwest Virginia. Antimicrob Agents Chemother (1995) 0.92
Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies. J Clin Microbiol (1998) 0.92
Pneumococcal meningitis in the North East Thames Region UK: epidemiology and molecular analysis of isolates. Epidemiol Infect (1996) 0.90
Emergence of penicillin-nonsusceptible Streptococcus pneumoniae invasive clones in Canada. J Clin Microbiol (2002) 0.90
Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program. Emerg Infect Dis (2015) 0.89
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob Agents Chemother (2006) 0.88
In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia. Antimicrob Agents Chemother (2000) 0.88
Sentinel surveillance: a reliable way to track antibiotic resistance in communities? Emerg Infect Dis (2002) 0.88
Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis (1997) 0.88
Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob Agents Chemother (2002) 0.87
Interleukin-10 negatively regulates local cytokine and chemokine production but does not influence antibacterial host defense during murine pneumococcal meningitis. Infect Immun (2003) 0.86
Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008. Antimicrob Agents Chemother (2012) 0.86
Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother (2002) 0.85
Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections. Antimicrob Agents Chemother (1996) 0.85
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother (2000) 0.84
Emergence of penicillin-resistant Streptococcus pneumoniae in southern Ontario, 1993-94. Can J Infect Dis (1995) 0.84
PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan. PLoS One (2013) 0.83
Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob Agents Chemother (1997) 0.82
Antimicrobial susceptibilities and serotypes of invasive Streptococcus pneumoniae strains in Switzerland. J Clin Microbiol (1995) 0.81
Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae. J Clin Microbiol (1999) 0.81
Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Ther Clin Risk Manag (2015) 0.80
Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in central Australia. J Clin Microbiol (1996) 0.80
The world's microbiology laboratories can be a global microbial sensor network. Biomedica (2014) 0.79
Changing parents' opinions regarding antibiotic use in primary care. Eur J Pediatr (2010) 0.79
Pneumococcal Pneumonia. Curr Infect Dis Rep (1999) 0.79
Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis (1998) 0.78
Peptide mimic of phosphorylcholine, a dominant epitope found on Streptococcus pneumoniae. Infect Immun (2000) 0.78
Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents. Antimicrob Agents Chemother (2003) 0.78
Structural characterization of Zn(II)-, Co(II)-, and Mn(II)-loaded forms of the argE-encoded N-acetyl-L-ornithine deacetylase from Escherichia coli. J Inorg Biochem (2012) 0.77
Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1995) 0.77
Wagging the dog: antibiotic use and the emergence of resistance. J Gen Intern Med (1999) 0.75
Meningitis in a Canadian adult due to high level penicillin-resistant, cefotaxime-intermediate Streptococcus pneumoniae. Can J Infect Dis (1996) 0.75
Emerging pathogens. An epidemiologist's perspective on the problem and priorities for the future. West J Med (1996) 0.75
Determination of trimethoprim-sulfamethoxazole resistance in Streptococcus pneumoniae by using the E test with Mueller-Hinton agar supplemented with sheep or horse blood may be unreliable. The Pneumococcal Study Group. J Clin Microbiol (1999) 0.75
High prevalence of penicillin-nonsusceptible Streptococcus pneumoniae at a community hospital in Oklahoma. Emerg Infect Dis (2000) 0.75
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (2001) 16.97
Recognition of group D streptococcal species of human origin by biochemical and physiological tests. Appl Microbiol (1972) 13.09
Physiological differentiation of viridans streptococci. J Clin Microbiol (1977) 11.17
Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med (1999) 10.21
Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol (1995) 8.36
Presumptive identification of group A, B, and D streptococci. Appl Microbiol (1974) 8.23
Distribution by serological type of group B streptococci isolated from a variety of clinical material over a five-year period (with special reference to neonatal sepsis and meningitis). Infect Immun (1973) 7.01
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
Campylobacter cinaedi (sp. nov.) and Campylobacter fennelliae (sp. nov.): two new Campylobacter species associated with enteric disease in homosexual men. J Infect Dis (1985) 6.32
Comparison of several laboratory media for presumptive identification of enterococci and group D streptococci. Appl Microbiol (1973) 6.17
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Presumptive identification of group D streptococci: the bile-esculin test. Appl Microbiol (1970) 6.00
Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother (1993) 5.96
Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J (1999) 5.88
Recovery of resistant enterococci during vancomycin prophylaxis. J Clin Microbiol (1988) 5.71
Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Clin Microbiol Rev (1995) 5.51
Chronic fatigue in adolescents. Pediatrics (1991) 5.24
The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med (1995) 5.18
Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med (2000) 4.20
Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother (1997) 4.20
Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis (1991) 4.00
Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J (1992) 3.84
Nonhemolytic group B streptococci of human, bovine, and ichthyic origin. Infect Immun (1973) 3.81
Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis (1999) 3.77
Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J Infect Dis (1995) 3.66
Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase. JAMA (2000) 3.64
Plasmid fingerprinting. A tool for bacterial strain identification and surveillance of nosocomial and community-acquired infections. Clin Lab Med (1985) 3.48
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA (2000) 3.42
Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Agents Chemother (1992) 3.39
Changing epidemiology of group A streptococcal infection in the USA. Lancet (1990) 3.35
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA (1993) 3.31
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis (1997) 3.29
The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis (1996) 3.26
Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis (1998) 3.18
Phylogenetic analysis of some Aerococcus-like organisms from clinical sources: description of Helcococcus kunzii gen. nov., sp. nov. Int J Syst Bacteriol (1993) 3.16
Evaluation of the Rapid Strep system for the identification of clinical isolates of Streptococcus species. J Clin Microbiol (1984) 3.16
Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis. Antimicrob Agents Chemother (1974) 3.06
Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol (2001) 3.06
Antibiotics synergism: enhanced susceptibility of group D streptococci to certain antibiotic combinations. Antimicrob Agents Chemother (Bethesda) (1970) 3.05
The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis (1992) 3.04
Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother (1994) 3.02
A case-control study of hantavirus pulmonary syndrome during an outbreak in the southwestern United States. J Infect Dis (1995) 2.95
Evaluation of commercial latex agglutination reagents for grouping streptococci. J Clin Microbiol (1979) 2.95
Specimen volume versus yield in the BACTEC blood culture system. J Clin Microbiol (1985) 2.91
Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med (1999) 2.87
Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med (2000) 2.85
Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis (1996) 2.85
Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med (1980) 2.85
Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother (2000) 2.80
High interlaboratory reproducibility of DNA sequence-based typing of bacteria in a multicenter study. J Clin Microbiol (2006) 2.80
Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis (1990) 2.80
Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol (1994) 2.77
Presumptive identification of group A, B, and D streptococci on agar plate media. J Clin Microbiol (1979) 2.72
Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother (1995) 2.64
Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan. Lancet (1991) 2.63
Factors affecting the clinical value of microscopy for acid-fast bacilli. Rev Infect Dis (1984) 2.57
An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med (1998) 2.56
Presumptive identification of streptococci with a new test system. J Clin Microbiol (1982) 2.55
Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem? J Clin Microbiol (1989) 2.51
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother (1999) 2.49
Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol (1992) 2.45
Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol (1994) 2.44
Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA (2001) 2.40
gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother (1998) 2.35
Prevalence and characterization of hippurate-negative Campylobacter jejuni in King County, Washington. J Clin Microbiol (1987) 2.33
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Detection of vancomycin-resistant enterococci in fecal samples by PCR. J Clin Microbiol (1997) 2.32
Evaluation of Alamar colorimetric MIC method for antimicrobial susceptibility testing of gram-negative bacteria. J Clin Microbiol (1994) 2.31
Turnaround times for mycobacterial cultures. J Clin Microbiol (1997) 2.30
A high molecular weight antigen in Legionnaires' disease bacterium: isolation and partial characterization. Ann Intern Med (1979) 2.29
Multicenter evaluation of epidemiological typing of methicillin-resistant Staphylococcus aureus strains by repetitive-element PCR analysis. The European Study Group on Epidemiological Markers of the ESCMID. J Clin Microbiol (2000) 2.28
The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol (1999) 2.28
Survey of plasmids and resistance factors in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother (1985) 2.27
Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med (1986) 2.26
Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group. J Clin Microbiol (1992) 2.23
Possible nosocomial transmission of group B streptococci in a newborn nursery. J Pediatr (1975) 2.21
Hospital characteristics associated with colonization of water systems by Legionella and risk of nosocomial legionnaires' disease: a cohort study of 15 hospitals. Infect Control Hosp Epidemiol (1999) 2.20
Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr (1996) 2.17
Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis (1999) 2.16
Role of clinical microbiology laboratories in the management and control of infectious diseases and the delivery of health care. Clin Infect Dis (2001) 2.14
Granulicatella and Abiotrophia species from human clinical specimens. J Clin Microbiol (2001) 2.14
Sleep estimation from wrist movement quantified by different actigraphic modalities. J Neurosci Methods (2001) 2.13
Specificity study of kits for detection of group A streptococci directly from throat swabs. J Clin Microbiol (1987) 2.10
Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA (1999) 2.09
Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics. J Infect Dis (1986) 2.04
Rapid identification of enterococci. J Clin Microbiol (1983) 2.03
Detection of Tn917-like sequences within a Tn916-like conjugative transposon (Tn3872) in erythromycin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 2.03
Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies. Pediatr Infect Dis J (1995) 2.00
Two percent sodium chloride is required for susceptibility testing of staphylococci with oxacillin when using agar-based dilution methods. J Clin Microbiol (1993) 1.97
Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother (1995) 1.96
Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg Infect Dis (1997) 1.96
Vibrio parahaemolyticus gastroenteritis. An outbreak associated with raw oysters in the Pacific northwest. Diagn Microbiol Infect Dis (1984) 1.96
Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother (1990) 1.93